肿瘤细胞治疗研究
英文原题：VA/VHAG alternating consolidation regimen combined with umbilical cord blood and mesenchymal stem cell infusion for the treatment of high-risk MDS patients who are unfit for transplantation: a case report and literature review.
这些治疗联合使用显示出良好的疗效。
对于不适合移植的高危骨髓增生异常综合征（MDS）患者，唯一治疗选择是持续使用去甲基化药物（HMA）。近年来虽开发了一些新的 HMA 联合方案及作用机制不同的其他药物，但尚未取得突破。在临床实践中，作者逐步探索了多种新方法：诱导治疗采用改良 VIALE-A（VA）方案，巩固期交替使用改良 VA 和 VHAG 方案。对微小残留病（MRD）持续阳性的部分患者给予 HLA 不匹配脐带血；对造血恢复不佳的患者则额外输注间充质干细胞。上述治疗取得了较好疗效。本文介绍一名典型患者的完整治疗过程，并回顾相关文献。
The only treatment option for high-risk MDS patients unfit for transplantation is continuous treatment with a hypomethylating agent (HMA). In this context, some new combination HMA regimens and other drugs with different mechanisms of action have been developed recently; however, no breakthroughs have been made. In our clinical practice, we have gradually explored various new methods-induction therapy with a modified VIALE-A (VA) regimen and an alternating regimen of modified VA and VHAG for the consolidation period. Some patients who were persistently positive for MRD were treated with HLA-mismatched umbilical cord blood, and patients with poor hematopoietic recovery additionally received mesenchymal stem cells infusion. Together, these treatments showed good efficacy. Here, the total treatment process for a typical patient is described, and a review of the literature is provided.
MEMBER ACCOUNT
登录成功会直接打开下一页。
